Physician profile
Ashwini Pramod Mehta
NPI 1174800908
$100,181.57
in general payments reported to CMS, 2019-2025
27 companies · $40K in 2025
The $40K reported for 2025 was more than what 90% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $828 · 2021: $2,605 · 2022: $3,066 · 2023: $2,144 · 2024: $2,784 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $6,773 · Food and Beverage: $6,642 · Travel and Lodging: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,737.50 |
| Consulting Fee | $6,772.50 |
| Food and Beverage | $6,641.98 |
| Travel and Lodging | $4,069.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox Ltd | $47,300.00 | 2019 | |
| Madrigal Pharmaceuticals | $39,494.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $3,162.55 | 2019-2024 | Ocaliva |
| Abbvie INC. | $3,101.99 | 2019-2025 | |
| Genentech USA, INC. | $1,405.85 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,360.19 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $1,154.58 | 2021-2025 | |
| Eisai INC. | $913.43 | 2020-2025 | |
| Pfizer INC. | $644.30 | 2019 | |
| Dova Pharmaceuticals | $319.63 | 2020-2021 | |
| Novo Nordisk INC | $225.52 | 2021-2025 | Wegovy |
| Biotronik INC. | $173.47 | 2020-2023 | Biomonitor |
| Sirtex Medical INC | $139.67 | 2023 | Sir-Spheres Microspheres |
| Amgen INC. | $139.34 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $138.33 | 2020-2025 | Livtencity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $132.66 | 2024-2025 | Iqirvo, Bylvay |
| Sobi, INC | $101.70 | 2022 | |
| Intra-Sana Laboratories | $71.52 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Dynavax Technologies Corporation | $39.62 | 2022-2023 | Heplisav-B |
| Merck Sharp & Dohme LLC | $32.98 | 2023 | Dificid, Prevymis |
| Fujifilm Healthcare Americas Corporation | $27.72 | 2025 | |
| Pentax of America, INC. | $26.84 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Sequana Medical US INC. | $24.29 | 2025 | Alfapump System |
| Mirum Pharmaceuticals, INC. | $20.16 | 2025 | Livmarli |
| Eton Pharmaceuticals, INC. | $16.82 | 2025 | Carglumic Acid, Nitisinone, Betaine Anhydrous |
| Ethicon US, LLC | $13.46 | 2023 | Neuwave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwini Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.